China News Service, Beijing, January 28 (Reporter Li Chun) "Some people say that atopic dermatitis is diabetes in dermatology and hypertension in dermatology. We understand that it is a common and chronic disease in this way." It was held on the 27th. At an online media communication meeting, Zhang Jianzhong, director of the Dermatology Department of Peking University People's Hospital, said that there are still many unmet needs in the treatment of atopic dermatitis.

  The media communication on the day will focus on atopic dermatitis. Three experts from Peking University People's Hospital, including Zhang Jianzhong, will discuss this topic and introduce the difficulties and precautions of the diagnosis and treatment of atopic dermatitis.

The “Beijing Diagnosis and Treatment Map of Atopic Dermatitis” was released on the same day, so that patients can get standardized treatment for atopic dermatitis according to the map.

Photo courtesy of the conference organizer

  Zhang Jianzhong said that the eczema often referred to by the Chinese people is basically what the industry calls atopic dermatitis.

The disease is very common. It is estimated that 10% to 15% of Chinese children have varying degrees of atopic dermatitis, and about 5% to 8% of adults suffer from the disease.

  Not only in China, the treatment of atopic dermatitis is also a challenge globally.

Zhang Jianzhong said that the reason lies in its various manifestations. Some patients have mild symptoms, some are more serious, and even severe to erythroderma or exfoliative dermatitis. More than 90% of the skin area is rash with exudation, Severe itching, unable to sleep.

The patient's quality of life is therefore greatly affected.

  He said that the treatment of relatively mild atopic dermatitis is mainly used outside the medicine, and the medium-degree patients are outside the medicine and oral medicine.

About 10% to 20% of patients are serious, and immunosuppressants were used in the past. About 70%, 80% of people will be effective.

However, many immunosuppressive agents have side effects and cannot be used for a long time. They will eventually usher in treatment failure, and patients will never get rid of the torment of disease recurrence.

  At the communication meeting that day, the experts at the meeting mentioned an innovative drug called Dabitol (duprolizumab injection).

The drug has been officially listed in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2020)" for the treatment of moderate to severe atopic dermatitis that is ineffective, contraindicated or intolerant to traditional treatments.

According to the communication meeting, before the new version of the medical insurance catalog is officially implemented, starting from January 25, 2021, the relevant terminal pharmacies may significantly reduce the retail price of Dabituo, in order to reduce the burden of medication for patients with atopic dermatitis and increase the drug Accessibility.

  Feng Yufei, director of the Department of Pharmacy of Peking University People's Hospital, said that in 2020, many new drugs will have the opportunity to enter medical insurance negotiations and medical insurance adjustments after they have passed the national approval, which is of great help to ordinary people.

Judging from the adjustment of the medical insurance catalog last year, the scope of medicines has expanded a lot compared to the past. It not only focuses on tumors, rare diseases, but also new coronary pneumonia, medicines for children, etc., covering a wide range and will benefit more patients.

  Feng Yufei further enumerated several aspects of patient benefit.

First of all, compared with conventional drugs, innovative drugs generally have better efficacy.

The second is the safety of drugs.

In addition, after the adjustment of medical insurance, the price of medicines negotiated has dropped a lot. For ordinary people and patients, the availability of medicines has been greatly improved. Many patients can use and afford medicines.

After the drugs entered the medical insurance, the proportion of personal payment was reduced, and the affordability was greatly improved.

  In addition to medicines, the population’s lack of awareness of atopic dermatitis, and irregular diagnosis and treatment are also a major difficulty in the treatment of the disease.

The “Beijing Diagnosis and Treatment Map of Atopic Dermatitis” was released on the same day, so that patients can get standardized treatment for atopic dermatitis according to the map.

Photo courtesy of the conference organizer

  According to Zhao Yan, deputy chief physician of the Department of Dermatology, Peking University People's Hospital, the prevalence of atopic dermatitis in China has gradually increased in the past few decades, with a high incidence but a low diagnosis.

Many clinically considered eczema, refractory eczema, and chronic eczema are essentially atopic dermatitis, but in the past, people had insufficient diagnosis and understanding of them.

  Zhao Yan pointed out that atopic dermatitis is a type 2 inflammatory disease with IL-4/IL-13 as the core factor. It is already an independent disease that can be clearly diagnosed clinically, but many patients are still misdiagnosed.

  Zhang Jianzhong said that untimely and irregular diagnosis and treatment are important reasons for recurrent atopic dermatitis. Even if the patient is diagnosed, the treatment effect is not satisfactory.

"The disease has not been controlled repeatedly for a long time, and many patients go around after trying various treatments and even give up treatment." In recent years, my country has been very effective in the diagnosis, treatment and prevention of atopic dermatitis. In a safe way, patients only need to find the right hospital to get a clear diagnosis.

  The media communication meeting that day also released the "Atopic Dermatitis Diagnosis and Treatment Map in Beijing".

"With the official release of the diagnosis and treatment map for atopic dermatitis in Beijing, patients can get standardized treatment according to the diagram." Zhang Jianzhong said.

  If moderate to severe atopic dermatitis is not well controlled, it will seriously affect the quality of life of patients and their families.

Zhang Jianzhong also pointed out that when patients have recurrent symptoms of severe itching and dry skin, followed by severe skin lesions, sleep interruption and other disease burdens, they should go to a professional hospital or specialist clinic with diagnosis and treatment capabilities for a clear diagnosis and Symptomatic treatment.

This will effectively alleviate or reduce the recurrence of patients, and at the same time can effectively prevent the occurrence of other comorbidities such as allergic asthma and allergic rhinitis.

(Finish)